Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.

Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, Gaida K, Holt T, Knutson CG, Koppada N, Lanman BA, Werner J, Rapaport AS, San Miguel T, Ortiz R, Osgood T, Sun JR, Zhu X, McCarter JD, Volak LP, Houk BE, Fakih MG, O'Neil BH, Price TJ, Falchook GS, Desai J, Kuo J, Govindan R, Hong DS, Ouyang W, Henary H, Arvedson T, Cee VJ, Lipford JR.

Nature. 2019 Nov;575(7781):217-223. doi: 10.1038/s41586-019-1694-1. Epub 2019 Oct 30.

PMID:
31666701
2.

Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance).

Yuan C, Sato K, Hollis BW, Zhang S, Niedzwiecki D, Ou FS, Chang IW, O'Neil BH, Innocenti F, Lenz HJ, Blanke CD, Goldberg RM, Venook AP, Mayer RJ, Fuchs CS, Meyerhardt JA, Ng K.

Clin Cancer Res. 2019 Dec 15;25(24):7497-7505. doi: 10.1158/1078-0432.CCR-19-0877. Epub 2019 Sep 23.

PMID:
31548349
3.

First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors.

Piha-Paul SA, Sachdev JC, Barve M, LoRusso P, Szmulewitz R, Patel SP, Lara PN Jr, Chen X, Hu B, Freise KJ, Modi D, Sood A, Hutti JE, Wolff J, O'Neil BH.

Clin Cancer Res. 2019 Nov 1;25(21):6309-6319. doi: 10.1158/1078-0432.CCR-19-0578. Epub 2019 Aug 16.

PMID:
31420359
4.

Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405.

Guercio BJ, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Sato K, Ng K, Van Blarigan E, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA.

J Clin Oncol. 2019 Oct 10;37(29):2620-2631. doi: 10.1200/JCO.19.01019. Epub 2019 Aug 13.

5.

A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer.

Davis SL, Cardin DB, Shahda S, Lenz HJ, Dotan E, O'Neil BH, Kapoun AM, Stagg RJ, Berlin J, Messersmith WA, Cohen SJ.

Invest New Drugs. 2019 Jul 23. doi: 10.1007/s10637-019-00824-1. [Epub ahead of print]

PMID:
31338636
6.

Evaluation of a locked nucleic acid form of antisense oligo targeting HIF-1α in advanced hepatocellular carcinoma.

Wu J, Contratto M, Shanbhogue KP, Manji GA, O'Neil BH, Noonan A, Tudor R, Lee R.

World J Clin Oncol. 2019 Mar 24;10(3):149-160. doi: 10.5306/wjco.v10.i3.149.

7.

Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer.

Sanoff HK, Moon DH, Moore DT, Boles J, Bui C, Blackstock W, O'Neil BH, Subramaniam S, McRee AJ, Carlson C, Lee MS, Tepper JE, Wang AZ.

Nanomedicine. 2019 Jun;18:189-195. doi: 10.1016/j.nano.2019.02.021. Epub 2019 Mar 8.

PMID:
30858085
8.

T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.

Ott PA, Bang YJ, Piha-Paul SA, Razak ARA, Bennouna J, Soria JC, Rugo HS, Cohen RB, O'Neil BH, Mehnert JM, Lopez J, Doi T, van Brummelen EMJ, Cristescu R, Yang P, Emancipator K, Stein K, Ayers M, Joe AK, Lunceford JK.

J Clin Oncol. 2019 Feb 1;37(4):318-327. doi: 10.1200/JCO.2018.78.2276. Epub 2018 Dec 13.

PMID:
30557521
9.

Social correlates of mental health in gastrointestinal cancer patients and their family caregivers: Exploring the role of loneliness.

Secinti E, Rand KL, Johns SA, O'Neil BH, Helft PR, Shahda S, Jalal SI, Mosher CE.

Support Care Cancer. 2019 Jun;27(6):2077-2086. doi: 10.1007/s00520-018-4467-8. Epub 2018 Sep 17.

PMID:
30225573
10.

Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.

Sehdev A, Gbolahan O, Hancock BA, Stanley M, Shahda S, Wan J, Wu HH, Radovich M, O'Neil BH.

Clin Cancer Res. 2018 Dec 15;24(24):6204-6211. doi: 10.1158/1078-0432.CCR-18-1472. Epub 2018 Aug 21.

11.

Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.

Sanoff HK, Goldberg RM, Ivanova A, O'Reilly S, Kasbari SS, Kim RD, McDermott R, Moore DT, Zamboni W, Grogan W, Cohn AL, Bekaii-Saab TS, Leonard G, Ryan T, Olowokure OO, Fernando NH, McCaffrey J, El-Rayes BF, Horgan AM, Sherrill GB, Yacoub GH, O'Neil BH.

Cancer. 2018 Aug 1;124(15):3118-3126. doi: 10.1002/cncr.31552. Epub 2018 Jun 15.

12.

Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).

Li M, Mulkey F, Jiang C, O'Neil BH, Schneider BP, Shen F, Friedman PN, Momozawa Y, Kubo M, Niedzwiecki D, Hochster HS, Lenz HJ, Atkins JN, Rugo HS, Halabi S, Kelly WK, McLeod HL, Innocenti F, Ratain MJ, Venook AP, Owzar K, Kroetz DL.

Clin Cancer Res. 2018 Oct 1;24(19):4734-4744. doi: 10.1158/1078-0432.CCR-17-1523. Epub 2018 Jun 5.

13.

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.

O'Neil BH, Wallmark JM, Lorente D, Elez E, Raimbourg J, Gomez-Roca C, Ejadi S, Piha-Paul SA, Stein MN, Abdul Razak AR, Dotti K, Santoro A, Cohen RB, Gould M, Saraf S, Stein K, Han SW.

PLoS One. 2017 Dec 28;12(12):e0189848. doi: 10.1371/journal.pone.0189848. eCollection 2017.

14.

Development of an AlphaLISA high throughput technique to screen for small molecule inhibitors targeting protein arginine methyltransferases.

Prabhu L, Chen L, Wei H, Demir Ö, Safa A, Zeng L, Amaro RE, O'Neil BH, Zhang ZY, Lu T.

Mol Biosyst. 2017 Nov 21;13(12):2509-2520. doi: 10.1039/c7mb00391a.

15.

Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.

Dadi N, Stanley M, Shahda S, O'Neil BH, Sehdev A.

Anticancer Res. 2017 Oct;37(10):5533-5539. Review.

16.

Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.

Gupta N, Hanley MJ, Venkatakrishnan K, Bessudo A, Rasco DW, Sharma S, O'Neil BH, Wang B, Liu G, Ke A, Patel C, Rowland Yeo K, Xia C, Zhang X, Esseltine DL, Nemunaitis J.

J Clin Pharmacol. 2018 Feb;58(2):180-192. doi: 10.1002/jcph.988. Epub 2017 Aug 11.

17.

A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.

Hanley MJ, Gupta N, Venkatakrishnan K, Bessudo A, Sharma S, O'Neil BH, Wang B, van de Velde H, Nemunaitis J.

J Clin Pharmacol. 2018 Jan;58(1):114-121. doi: 10.1002/jcph.987. Epub 2017 Aug 7.

PMID:
28783865
18.
19.

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.

Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB 3rd, Mulkerin DL, Mayer RJ, Blanke C.

JAMA. 2017 Jun 20;317(23):2392-2401. doi: 10.1001/jama.2017.7105.

20.

Examining the effect of peer helping in a coping skills intervention: a randomized controlled trial for advanced gastrointestinal cancer patients and their family caregivers.

Mosher CE, Secinti E, Johns SA, O'Neil BH, Helft PR, Shahda S, Jalal SI, Champion VL.

Qual Life Res. 2018 Feb;27(2):515-528. doi: 10.1007/s11136-017-1620-7. Epub 2017 Jun 10.

21.

Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts).

Bendell J, Hubbard J, O'Neil BH, Jonker D, Starodub A, Peyton J, Pitot H, Halfdanarson T, Nadeau B, Zubkus J, Adesunloye B, Edenfield J, Li YZ, Li W, Grothey A, Borodyansky L, Li CJ.

Ann Oncol. 2017 Jun;28 Suppl 3:iii150-iii151. doi: 10.1093/annonc/mdx302.002. No abstract available.

22.

Immortal time bias or sorafenib effect in elderly patients with HCC?

Sanoff HK, Chang Y, Lund JL, O'Neil BH, Dusetzina SB.

Hepatology. 2017 Aug;66(2):678-679. doi: 10.1002/hep.29250. Epub 2017 Jun 28. No abstract available.

23.

Locoregional and systemic therapy for hepatocellular carcinoma.

Gbolahan OB, Schacht MA, Beckley EW, LaRoche TP, O'Neil BH, Pyko M.

J Gastrointest Oncol. 2017 Apr;8(2):215-228. doi: 10.21037/jgo.2017.03.13. Review.

24.

Clinical Pathways: Management of Quality and Cost in Oncology Networks in the Metastatic Colorectal Cancer Setting.

Ellis PG, O'Neil BH, Earle MF, McCutcheon S, Benson H, Krebs M, Lokay K, Barry A.

J Oncol Pract. 2017 May;13(5):e522-e529. doi: 10.1200/JOP.2016.019232. Epub 2017 Apr 5.

PMID:
28379722
25.

A Multidisciplinary Approach to Pancreas Cancer in 2016: A Review.

Fogel EL, Shahda S, Sandrasegaran K, DeWitt J, Easler JJ, Agarwal DM, Eagleson M, Zyromski NJ, House MG, Ellsworth S, El Hajj I, O'Neil BH, Nakeeb A, Sherman S.

Am J Gastroenterol. 2017 Apr;112(4):537-554. doi: 10.1038/ajg.2016.610. Epub 2017 Jan 31. Review.

26.

A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan.

Cleary JM, McRee AJ, Shapiro GI, Tolaney SM, O'Neil BH, Kearns JD, Mathews S, Nering R, MacBeath G, Czibere A, Sharma S, Korn WM.

Invest New Drugs. 2017 Feb;35(1):68-78. doi: 10.1007/s10637-016-0399-7. Epub 2016 Nov 16.

PMID:
27853996
27.

Mental health outcomes during colorectal cancer survivorship: a review of the literature.

Mosher CE, Winger JG, Given BA, Helft PR, O'Neil BH.

Psychooncology. 2016 Nov;25(11):1261-1270. doi: 10.1002/pon.3954. Epub 2015 Aug 27. Review.

28.

Positive changes among patients with advanced colorectal cancer and their family caregivers: a qualitative analysis.

Mosher CE, Adams RN, Helft PR, O'Neil BH, Shahda S, Rattray NA, Champion VL.

Psychol Health. 2017 Jan;32(1):94-109. Epub 2016 Oct 24.

29.

Summary of emerging personalized medicine in neuroendocrine tumors: are we on track?

Lee MS, O'Neil BH.

J Gastrointest Oncol. 2016 Oct;7(5):804-818. Review.

30.

A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.

Heinemann V, Rivera F, O'Neil BH, Stintzing S, Koukakis R, Terwey JH, Douillard JY.

Eur J Cancer. 2016 Nov;67:11-20. doi: 10.1016/j.ejca.2016.07.019. Epub 2016 Sep 1.

31.

Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer.

Saif MW, Knost JA, Chiorean EG, Kambhampati SR, Yu D, Pytowski B, Qin A, Kauh JS, O'Neil BH.

Cancer Chemother Pharmacol. 2016 Oct;78(4):815-24. doi: 10.1007/s00280-016-3134-3. Epub 2016 Aug 26.

PMID:
27566701
32.

Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers.

Radovich M, Kiel PJ, Nance SM, Niland EE, Parsley ME, Ferguson ME, Jiang G, Ammakkanavar NR, Einhorn LH, Cheng L, Nassiri M, Davidson DD, Rushing DA, Loehrer PJ, Pili R, Hanna N, Callaghan JT, Skaar TC, Helft PR, Shahda S, O'Neil BH, Schneider BP.

Oncotarget. 2016 Aug 30;7(35):56491-56500. doi: 10.18632/oncotarget.10606.

34.

Checkpoint inhibition for colorectal cancer: progress and possibilities.

Paul B, O'Neil BH, McRee AJ.

Immunotherapy. 2016 Jun;8(6):693-704. doi: 10.2217/imt-2016-0013. Review.

PMID:
27197538
35.

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.

Sanoff HK, Chang Y, Lund JL, O'Neil BH, Dusetzina SB.

Oncologist. 2016 Sep;21(9):1113-20. doi: 10.1634/theoncologist.2015-0478. Epub 2016 May 16.

36.

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

O'Neil BH, Scott AJ, Ma WW, Cohen SJ, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler AL, Olowokure OO, Baranda JC, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M, Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, Fanta P, Berlin J, McRee AJ, Maguire R, Wilhelm F, Maniar M, Jimeno A, Gomes CL, Messersmith WA.

Ann Oncol. 2016 Jun;27(6):1180. doi: 10.1093/annonc/mdw095. Epub 2016 Mar 3. No abstract available.

37.

A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium study.

Cohen SJ, O'Neil BH, Berlin J, Ames P, McKinley M, Horan J, Catalano PM, Davies A, Weekes CD, Leichman L.

Cancer Chemother Pharmacol. 2016 Apr;77(4):693-701. doi: 10.1007/s00280-016-2981-2. Epub 2016 Feb 17.

PMID:
26886016
38.

Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer.

Leichman L, Groshen S, O'Neil BH, Messersmith W, Berlin J, Chan E, Leichman CG, Cohen SJ, Cohen D, Lenz HJ, Gold P, Boman B, Fielding A, Locker G, Cason RC, Hamilton SR, Hochster HS.

Oncologist. 2016 Feb;21(2):172-7. doi: 10.1634/theoncologist.2015-0319. Epub 2016 Jan 19.

39.

Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts.

Lipner MB, Marayati R, Deng Y, Wang X, Raftery L, O'Neil BH, Yeh JJ.

PLoS One. 2016 Jan 13;11(1):e0147113. doi: 10.1371/journal.pone.0147113. eCollection 2016.

40.

Family caregiving challenges in advanced colorectal cancer: patient and caregiver perspectives.

Mosher CE, Adams RN, Helft PR, O'Neil BH, Shahda S, Rattray NA, Champion VL.

Support Care Cancer. 2016 May;24(5):2017-2024. doi: 10.1007/s00520-015-2995-z. Epub 2015 Nov 4.

41.

A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors.

McRee AJ, Sanoff HK, Carlson C, Ivanova A, O'Neil BH.

Invest New Drugs. 2015 Dec;33(6):1225-31. doi: 10.1007/s10637-015-0298-3. Epub 2015 Oct 21.

42.

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

O'Neil BH, Scott AJ, Ma WW, Cohen SJ, Leichman L, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler L, Olowokure OO, Baranda JC, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M, Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, Fanta P, Berlin J, McRee AJ, Maguire R, Wilhelm F, Maniar M, Jimeno A, Gomes CL, Messersmith WA.

Ann Oncol. 2015 Dec;26(12):2505. doi: 10.1093/annonc/mdv477. Epub 2015 Oct 21. No abstract available.

43.

Trying to Understand Differing Results of FIRE-3 and 80405: Does the First Treatment Matter More Than Others?

O'Neil BH, Venook AP.

J Clin Oncol. 2015 Nov 10;33(32):3686-8. doi: 10.1200/JCO.2015.62.8495. Epub 2015 Aug 31. No abstract available.

PMID:
26324365
44.

Current management of gastrointestinal stromal tumors: Surgery, current biomarkers, mutations, and therapy.

Valsangkar N, Sehdev A, Misra S, Zimmers TA, O'Neil BH, Koniaris LG.

Surgery. 2015 Nov;158(5):1149-64. doi: 10.1016/j.surg.2015.06.027. Epub 2015 Aug 1. Review.

PMID:
26243346
45.

The Role of Aspirin, Vitamin D, Exercise, Diet, Statins, and Metformin in the Prevention and Treatment of Colorectal Cancer.

Sehdev A, O'Neil BH.

Curr Treat Options Oncol. 2015 Sep;16(9):43. doi: 10.1007/s11864-015-0359-z. Review.

PMID:
26187794
46.

(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.

Picozzi VJ, Ramanathan RK, Lowery MA, Ocean AJ, Mitchel EP, O'Neil BH, Guarino MJ, Conkling PR, Cohen SJ, Bahary N, Frank RC, Dragovich T, Bridges BB, Braiteh FS, Starodub AN, Lee FC, Gribbin TE, Richards DA, Lee M, Korn RL, Pandit-Taskar N, Goldsmith SJ, Intenzo CM, Sheikh A, Manzone TC, Horne H, Sharkey RM, Wegener WA, O'Reilly EM, Goldenberg DM, Von Hoff DD.

Eur J Cancer. 2015 Sep;51(14):1857-64. doi: 10.1016/j.ejca.2015.06.119. Epub 2015 Jul 14.

47.

The Role of HIPEC in Gastrointestinal Malignancies: Controversies and Conclusions.

McRee AJ, O'Neil BH.

Oncology (Williston Park). 2015 Jul;29(7):523-4, C3. No abstract available.

48.

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

O'Neil BH, Scott AJ, Ma WW, Cohen SJ, Leichman L, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler AL, Olowokure OO, Baranda JC, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M, Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, Fanta P, Berlin J, McRee AJ, Maguire R, Wilhelm F, Maniar M, Jimeno A, Gomes CL, Messersmith WA.

Ann Oncol. 2015 Sep;26(9):1923-9. doi: 10.1093/annonc/mdv264. Epub 2015 Jun 19. Erratum in: Ann Oncol. 2015 Dec;26(12):2505. Leichman, L [added]. Ann Oncol. 2016 Jun;27(6):1180.

49.

Circulating tumor cell detection using a parallel flow micro-aperture chip system.

Chang CL, Huang W, Jalal SI, Chan BD, Mahmood A, Shahda S, O'Neil BH, Matei DE, Savran CA.

Lab Chip. 2015 Apr 7;15(7):1677-88. doi: 10.1039/c5lc00100e.

PMID:
25687986
50.

Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma.

Sanoff HK, Kim R, Ivanova A, Alistar A, McRee AJ, O'Neil BH.

Invest New Drugs. 2015 Apr;33(2):505-9. doi: 10.1007/s10637-015-0209-7. Epub 2015 Jan 23.

Supplemental Content

Loading ...
Support Center